In this study, although it has been proven that TUSC7 acts as a tumor suppressor in gliomas and has the potential to be a biomarker, in vivo and in vitro experiments are still needed for further validation, thus providing bases for clinical transformation. The gene discussed is TUSC7; the disease is neoplasm.